MPH MD - NRX Pharmaceuticals Chief CoFounder
| NRXP Stock | USD 2.20 0.15 7.32% |
Insider
MPH MD is Chief CoFounder of NRX Pharmaceuticals
| Age | 68 |
| Address | 1201 Orange Street, Wilmington, DE, United States, 19801 |
| Phone | 484 254 6134 |
| Web | https://www.nrxpharma.com |
NRX Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.4566) % which means that it has lost $1.4566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.8261) %, meaning that it created substantial loss on money invested by shareholders. NRX Pharmaceuticals' management efficiency ratios could be used to measure how well NRX Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NRX Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 03/18/2025, Return On Equity is likely to grow to 1.14, though Return On Tangible Assets are likely to grow to (6.54). As of 03/18/2025, Non Current Liabilities Total is likely to grow to about 5.3 M, while Total Current Liabilities is likely to drop slightly above 16.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Eran MD | Biomx Inc | N/A | |
| Amro Albanna | Aditxt Inc | 55 | |
| Inbar GahaliSass | Biomx Inc | N/A | |
| Philip Ainslie | Lexaria Bioscience Corp | N/A | |
| Ramtin MD | RenovoRx | 59 | |
| James Foster | Virax Biolabs Group | 40 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| DDS MS | Aditxt Inc | 59 | |
| Angela Nelms | RenovoRx | 47 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 63 | |
| Merav Bassan | Biomx Inc | 59 | |
| Jason Davis | Virax Biolabs Group | 53 | |
| MD FACC | Longeveron LLC | 62 | |
| Pr Sorek | Biomx Inc | N/A | |
| Jonathan MBA | Biomx Inc | 48 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
| Gerald Goodman | Nutriband | 77 | |
| James CPA | Longeveron LLC | 58 | |
| Thomas CPA | Aditxt Inc | 51 | |
| Craig Esq | Cingulate | 51 | |
Management Performance
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.46 |
NRX Pharmaceuticals Leadership Team
Elected by the shareholders, the NRX Pharmaceuticals' board of directors comprises two types of representatives: NRX Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NRX. The board's role is to monitor NRX Pharmaceuticals' management team and ensure that shareholders' interests are well served. NRX Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NRX Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Suzanne Messere, Investor Relations | ||
| Michael Abrams, Chief Officer | ||
| Robert MIM, Chief Operations | ||
| Michael Kunz, Gen Sec | ||
| Stephen Esq, CEO Secretary | ||
| Richard Narido, Principal CFO | ||
| Molly Cogan, Sr Affairs | ||
| Seth Voorhees, CFO Treasurer | ||
| Dennis McBride, Chief Scientist | ||
| Matthew Duffy, Chief Therapeutics | ||
| Prof Javitt, CoFounder Board | ||
| Riccardo Panicucci, Chief Officer | ||
| MPH MD, Chief CoFounder | ||
| Philip Lavin, Chief Methodologist |
NRX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NRX Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.46 | ||||
| Current Valuation | 39.81 M | ||||
| Shares Outstanding | 16.92 M | ||||
| Shares Owned By Insiders | 16.37 % | ||||
| Shares Owned By Institutions | 5.94 % | ||||
| Number Of Shares Shorted | 1.15 M | ||||
| Price To Book | 2.90 X | ||||
| EBITDA | (18.5 M) | ||||
| Net Income | (25.13 M) |
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.